Transfusion Medicine

Blood is the one drug in the hospital that no factory can manufacture — every unit begins as an act of donation by another human being. Transfusion medicine is the discipline that makes it safe to move that living tissue from one person into another: matching donor and recipient at the level of red-cell antigens, splitting a single donation into targeted components, and catching the reactions that occur when the immune system meets blood it recognizes as foreign. For a clinician it is a daily practical skill (ordering the right product, checking the right identity) built on a beautiful piece of immunology.

Get it right and you rescue a patient exsanguinating in theatre. Get it wrong — the wrong unit to the wrong patient — and you can kill someone in minutes with a mismatched ABO transfusion. This page teaches the understanding behind the checklists.

Learning Objectives

• Explain the genetic and immunological basis of the ABO and Rh blood group systems.
• Describe the steps of pre-transfusion testing: grouping, antibody screening, and cross-matching.
• Match common blood components to their clinical indications and storage rules.
• Recognise, classify, and initiate management for acute and delayed transfusion reactions.
• Apply compatibility rules to emergency and massive-transfusion scenarios.

Quick Answer

The ABO system defines four groups (A, B, AB, O) by which sugar antigens sit on the red cell, and — crucially — everyone naturally makes antibodies against the antigens they lack. The Rh system adds the clinically dominant D antigen (RhD positive or negative). Before transfusion, the lab determines the patient's group, screens their plasma for atypical antibodies, and performs a cross-match confirming donor cells are compatible. Blood is usually given as separated components: packed red cells for oxygen-carrying capacity, platelets for thrombocytopenic bleeding, fresh frozen plasma and cryoprecipitate for coagulation factors. Transfusion reactions range from mild febrile or allergic responses to life-threatening acute haemolytic reactions, TRALI, and TACO. Karl Landsteiner's discovery of the ABO groups in 1901 turned transfusion from a lethal gamble into modern therapy.

Where It Came From

The motivation was death by transfusion. Through the seventeenth to nineteenth centuries, doctors attempting to transfuse blood — sometimes animal blood into humans — watched patients react violently and often die. Transfusion was so dangerous it was banned in several countries. Nobody understood why the same procedure sometimes helped and sometimes killed.

In 1901, the Austrian physician Karl Landsteiner mixed serum and red cells from his own laboratory colleagues in all combinations and noticed that some mixtures clumped (agglutinated) and others did not. From this simple experiment he deduced that human blood comes in distinct types defined by antigens on the red cell and matching antibodies in the serum. He named the first groups A, B, and C (later O); the AB group was described by his students Decastello and Sturli in 1902. This is why an ABO mismatch causes immediate clumping and haemolysis — the pre-formed antibodies were there all along. Landsteiner received the Nobel Prize in 1930, and in 1940, with Alexander Wiener, he described the Rh factor (named after the Rhesus monkey used in the experiments), explaining a major cause of haemolytic disease of the newborn and of delayed transfusion reactions.

Two further advances made large-scale transfusion possible: the discovery that sodium citrate could prevent clotting (anticoagulation, around 1914–1915), allowing blood to be stored rather than transfused vein-to-vein, and the development of blood banking and component separation through the twentieth century. The need each time was the same — make a life-saving therapy predictable and safe.

The ABO and Rh Blood Group Systems

ABO is built on sugars. The H antigen is a base structure on the red cell surface; the A gene adds N-acetylgalactosamine to make the A antigen, the B gene adds galactose to make the B antigen, and the O gene is non-functional, leaving H unmodified. So:

• Group A cells carry A antigen; plasma contains anti-B antibodies.
• Group B cells carry B antigen; plasma contains anti-A.
• Group AB cells carry both; plasma contains neither antibody — the universal recipient.
• Group O cells carry neither A nor B; plasma contains both anti-A and anti-B — the red cells are the universal donor.

The defining feature of ABO is that the antibodies are naturally occurring (mostly IgM), present from infancy without prior exposure, probably provoked by gut bacteria carrying similar sugars. Because they are IgM and complement-fixing, an ABO-incompatible transfusion causes immediate, intravascular haemolysis — the most dangerous reaction in the field.

Rh is a protein system with many antigens; the D antigen dominates clinically. About 85% of people are RhD positive. Unlike ABO, anti-D is not naturally occurring — it forms only after exposure (a mismatched transfusion or a pregnancy where an RhD-negative mother carries an RhD-positive fetus). This is why an RhD-negative woman of childbearing potential must never receive RhD-positive blood except in dire emergency, and why anti-D immunoglobulin (RhoGAM) is given prophylactically in pregnancy to prevent sensitisation and future haemolytic disease of the newborn.

Pre-Transfusion Testing and Cross-Matching

Safety comes from three lab steps:

1. Blood grouping (typing). Forward typing tests the patient's red cells with known anti-A and anti-B reagents; reverse typing tests the patient's plasma against known A and B cells. The two must agree — a built-in double check. RhD status is determined separately.
2. Antibody screen. The patient's plasma is tested against reagent red cells expressing common clinically significant antigens (Rh, Kell, Duffy, Kidd, etc.) to detect atypical antibodies from prior transfusion or pregnancy.
3. Cross-match. The final compatibility test between the specific donor unit and the patient. A full (serological) cross-match incubates patient plasma with donor cells, often via the antiglobulin (Coombs) phase, and looks for agglutination. If the antibody screen is negative, many labs use an electronic (computer) cross-match that matches records without physical mixing, saving time.

Worked example. A patient is grouped: forward typing agglutinates with anti-B only; reverse typing agglutinates with A cells only. The cells carry B antigen and the plasma has anti-A — the patient is group B. They can receive group B or group O red cells, but not A or AB (which would meet the anti-A). If also RhD negative, give RhD-negative units.

In an emergency with no time to type, give O RhD-negative packed cells (or O RhD-positive for males and older women if D-negative stock is short). For plasma products the compatibility is reversed: AB plasma is the universal donor plasma because it contains no anti-A or anti-B.

Blood Products and Their Uses

Whole blood is rarely transfused today; instead one donation is separated into components so each patient gets only what they need.

Component	Main contents	Typical indication	Storage
Packed red cells	Red cells, little plasma	Symptomatic anaemia, acute blood loss	2–6 degrees C, up to ~35–42 days
Platelets	Platelets in plasma	Thrombocytopenia, platelet dysfunction with bleeding	Room temp, agitated, ~5–7 days
Fresh frozen plasma (FFP)	All coagulation factors	Multiple factor deficiency, warfarin reversal when PCC unavailable, DIC	Frozen; thaw before use
Cryoprecipitate	Fibrinogen, factor VIII, vWF, XIII	Low fibrinogen, DIC, some factor deficiencies	Frozen

A useful rule of thumb: one unit of packed red cells raises haemoglobin by roughly 1 g/dL in an average adult. Modern practice favours restrictive transfusion — transfusing at a haemoglobin threshold around 7 g/dL in most stable patients rather than "topping up" to normal, because liberal transfusion offers no benefit and adds risk.

Real-World Applications

• Massive haemorrhage (trauma, obstetric bleeding, ruptured aneurysm): activate a massive transfusion protocol delivering red cells, plasma, and platelets in balanced ratios (often approximated as 1:1:1) to prevent dilutional coagulopathy.
• Elective surgery: a "group and save" (type and screen) is done pre-operatively; if bleeding risk is significant, units are cross-matched and reserved.
• Chronic transfusion (thalassaemia, myelodysplasia, sickle cell): recurrent transfusions cause iron overload, requiring iron chelation, and extended antigen matching to reduce alloimmunisation.
• Pregnancy: RhD-negative mothers receive anti-D prophylaxis; antibody screening detects sensitisation threatening the fetus.

Common Mistakes

1. Confusing universal donor for cells with universal donor for plasma. O is the universal red-cell donor (no A/B antigens), but AB is the universal plasma donor (no A/B antibodies). Students who apply the "O for everything" rule give incompatible plasma. Remember: cells and plasma follow opposite logic.
2. Assuming a valid cross-match means the transfusion is safe to give without checking identity. The single most common cause of fatal reactions is clerical error — the right blood to the wrong patient. Bedside identity checking (patient wristband against the unit) prevents ABO catastrophe; the lab work cannot.
3. Treating anti-D as naturally occurring like anti-A/anti-B. Anti-D forms only after exposure, so a first mismatched Rh transfusion may not cause an immediate reaction — but it sensitises the patient, causing a delayed haemolytic reaction later or haemolytic disease in a future pregnancy. Underestimating this leads to skipped anti-D prophylaxis.
4. Overtransfusing. Aiming for a "normal" haemoglobin in stable patients increases circulatory overload (TACO) and other risks without benefit; use restrictive thresholds.

Comparison and Connections

Feature	ABO system	Rh (D) system
Antigen type	Sugars on red cell	Protein
Antibodies	Naturally occurring (IgM)	Immune, after exposure (IgG)
Reaction on mismatch	Immediate intravascular haemolysis	Often delayed; crosses placenta
Main clinical danger	Acute fatal transfusion reaction	Haemolytic disease of the newborn, delayed reaction

Two reactions students confuse are TACO and TRALI. TACO (transfusion-associated circulatory overload) is a volume problem — too much fluid too fast, causing pulmonary oedema, hypertension, responds to diuretics. TRALI (transfusion-related acute lung injury) is an immune problem — donor antibodies triggering non-cardiogenic pulmonary oedema within 6 hours, with normal or low filling pressures, managed with respiratory support, not diuretics.

This topic connects to the immunology of antigen–antibody reactions, to the coagulation cascade behind plasma products, and to the pathophysiology of anaemia and haemorrhage. See ../../4._Pathology/index.md and ../../34._Immunology/index.md.

Practice Questions

Recall

Q: Which blood group is the universal red-cell donor, and why? A: Group O RhD-negative. Its red cells carry neither A, B, nor D antigen, so they will not be attacked by anti-A, anti-B, or anti-D in any recipient.

Understanding

Q: Why does an ABO-incompatible transfusion cause an immediate reaction while a first Rh-incompatible transfusion may not? A: ABO antibodies are naturally present (IgM, complement-fixing), so they attack incompatible cells at once, causing intravascular haemolysis. Anti-D is not pre-formed; it develops only after exposure, so the first mismatch sensitises rather than immediately harms — the danger comes with the next exposure.

Application

Q: A trauma patient is exsanguinating and unknown group. What red cells do you give and why? A: O RhD-negative packed cells, because they lack ABO and D antigens and can be given before grouping is complete. Switch to group-specific blood once the sample is typed.

Analysis

Q: A patient becomes acutely breathless and hypertensive 2 hours into a red-cell transfusion, with crackles and raised JVP. Contrast the two leading diagnoses and your action. A: TACO (circulatory overload) fits the hypertension, raised JVP, and fluid overload picture — stop or slow the transfusion, sit up, give oxygen and a diuretic. TRALI would show hypotension and non-cardiogenic oedema with normal filling pressures — supportive respiratory care instead. Here the hypertension and raised JVP point to TACO.

FAQ

Is O-negative really safe for everyone? For red cells in an emergency, yes — it lacks the major antigens. But O-negative plasma contains anti-A and anti-B, so O is not a universal plasma donor, and rare antibodies outside ABO/Rh can still cause problems, which is why full cross-matching is done whenever time allows.

Why can't AB-positive people donate red cells to everyone if they can receive from everyone? Because "universal recipient" and "universal donor" are opposites. AB cells carry both A and B antigens, so they would be attacked by anti-A or anti-B in most recipients. AB people are universal recipients of red cells but universal donors of plasma.

What actually happens in a fatal ABO mismatch? The recipient's anti-A or anti-B binds donor cells, activates complement, and causes massive intravascular haemolysis. This releases free haemoglobin and triggers shock, disseminated intravascular coagulation, and acute kidney injury — potentially within minutes of starting the transfusion.

How is a febrile non-haemolytic reaction different from a serious one? It is a common, benign fever from cytokines or recipient antibodies against donor white cells, without haemolysis. It is a diagnosis of exclusion — you must first stop the transfusion and rule out an acute haemolytic reaction before attributing symptoms to a simple febrile reaction.

Why give components instead of whole blood? One donation helps several patients, each receives only what they need (reducing volume and risk), and each component has optimal storage conditions — red cells refrigerated, platelets at room temperature, plasma frozen.

Quick Revision

• Landsteiner discovered ABO in 1901; Rh with Wiener in 1940.
• ABO antibodies are natural (IgM); anti-D forms only after exposure (IgG).
• O-neg = universal red-cell donor; AB = universal plasma donor.
• Pre-transfusion: group, antibody screen, cross-match.
• Emergency: give O RhD-negative red cells.
• Components: red cells (anaemia), platelets (thrombocytopenia), FFP (factors), cryoprecipitate (fibrinogen).
• Most fatal reactions are clerical — check patient identity at the bedside.
• Acute haemolytic (ABO) is the deadliest; distinguish TACO (overload, diurese) from TRALI (immune lung injury, support).
• Restrictive threshold: transfuse around Hb 7 g/dL in stable patients.

Related Topics

Prerequisites

• ../../34._Immunology/index.md — antigen–antibody reactions and complement
• ../../2._Physiology/index.md — blood composition and oxygen transport

Related Topics

• ../index.md — Hematology branch overview
• ../../4._Pathology/index.md — haemolysis and coagulation disorders

Next Topics

• Anemia and its classification (Hematology)
• Coagulation disorders and their management (Hematology)